Publications by authors named "Rainer Helbig"
Article Synopsis
- Credelio™ (lotilaner) is effective for treating flea and tick infestations in cats, with a single oral dose of 6-24 mg/kg evaluated in this study.* -
- The study involved two groups of cats: one treated with lotilaner and a control group, with significant reductions in adult fleas and flea egg production observed in the lotilaner group compared to controls.* -
- Lotilaner was well-tolerated, leading to a high efficacy rate in flea elimination, as nearly all adult fleas were killed within 24 hours, with minimal adverse effects noted.*
Background: Robenacoxib (Onsior™) is a non-steroidal anti-inflammatory drug developed for canine and feline use for the control of pain and inflammation. It is available as both tablets and solution for injection. The objective of this study was to evaluate the safety of the interchangeable use of commercially available robenacoxib formulations when administered to cats orally using 6 mg tablets and subcutaneously using a solution for injection containing 20 mg/mL.
View Article and Find Full Text PDFArticle Synopsis
- A blinded, randomized study assessed the effectiveness of lotilaner (Credelio) compared to a placebo in treating adult flea infestations in 20 dogs, dividing them into two treatment groups.
- The lotilaner group showed 100% efficacy in killing adult fleas and reduced flea egg production by 98.5% within 24 hours of treatment.
- The results indicate that a single dose of lotilaner can effectively eliminate fleas and prevent future infestations for at least 30 days.
Background: Robenacoxib is a non-steroidal anti-inflammatory drug available for canine and feline use for the control of pain and inflammation marketed as Onsior™. The aim of this target animal safety study was to evaluate the 6-month safety profile of oral robenacoxib administration. It was a randomized, negative-controlled, parallel group study.
View Article and Find Full Text PDFBackground: Robenacoxib (Onsior™) is a non-steroidal anti-inflammatory drug developed for canine and feline use for the control of pain and inflammation. It is available as both tablets and solution for injection. The objective of this safety study was to investigate the interchangeable use of two robenacoxib formulations in dogs using a novel study design alternating between oral tablets and subcutaneous injections.
View Article and Find Full Text PDFArticle Synopsis
- Oclacitinib and ciclosporin are immunomodulators used to treat canine atopic dermatitis, with oclacitinib providing rapid relief similar to prednisolone, which is used initially with ciclosporin to enhance its effectiveness.!* -
- In a study with 16 beagles divided into two groups, dogs received either oclacitinib alone or oclacitinib with ciclosporin for three weeks, with daily monitoring for adverse effects and regular blood tests to assess health.!* -
- The results showed that both treatments were well tolerated overall, with only minor issues like diarrhea and transient appetite loss noted, indicating that using both drugs together doesn’t increase side effects compared to using o